Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 3, 2014, Pages 653-657

  Koh, Youngil ^a   Lee, So Young ^a   Kim, Inho ^a   Kwon, Ji Hyun ^a   Yoon, Sung Soo ^a   Park, Seonyang ^a   Chung, Mi Hye ^a   Suh, Sung Yun ^a   Kim, Kwi Suk ^a   Kim, Hyang Sook ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

Anticonvulsants; Bortezomib; Multiple myeloma; Peripheral neuropathy; Subcutaneous

Indexed keywords

ANTICONVULSIVE AGENT; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; GABAPENTIN; MELPHALAN; PREDNISOLONE; PREGABALIN; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ASSESSMENT; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; HUMAN; INCIDENCE; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

AGED; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ASIAN CONTINENTAL ANCESTRY GROUP; BORONIC ACIDS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84907598721     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2555-0     Document Type: Article

References (13)

1. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS (2013) Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat Off J Korean Cancer Assoc 45(1):1-14. doi:10.4143/crt.2013.45.1.1
2. Dimopoulos MA, Terpos E (2010) Multiple myeloma. Ann Oncol Off J Eur Soc Med Oncol ESMO 21(Suppl 7):vii143-vii150. doi:10.1093/annonc/mdq370
3. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato A (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol Off J Am Soc Clin Oncol 24(19):3113-3120. doi:10.1200/JCO.2005.04.7779 (Pubitemid 46638949)
4. Bang SM, Lee JH, Yoon SS, Park S, Min CK, Kim CC, Suh C, Sohn SK, Min YH, Lee JJ, Kim K, Seong CM, Yoon HJ, Cho KS, Jo DY, Lee KH, Lee NR, Kim CS, Korean Multiple Myeloma Working P (2006) A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma. Int J Hematol 83(4):309-313. doi:10.1532/IJH97.A30512 (Pubitemid 43807574)
5. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12(5):431-440. doi:10.1016/S1470-2045(11)70081-X
6. Chen ML (2006) Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 45(10):957-964. doi:10.2165/00003088-200645100-00001
7. Vague P, Brunetti O, Valet AM, Attali I, Lassmann-Vague V, Vialettes B (1988) Increased prevalence of neurologic complications among insulin dependent diabetic patients of Algerian origin. Diabete Metab 14(6):706-711 (Pubitemid 19047214)
8. Jannot MF, Raccah D, De La Tour DD, Coste T, Vague P (2002) Genetic and environmental regulation of Na/K adenosine triphosphatase activity in diabetic patients. Metab, Clin Exp 51(3):284-291 (Pubitemid 34232627)
9. Kyle RA, Rajkumar SV (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23(1):3-9. doi:10.1038/leu.2008.291
10. Kamimura T, Miyamoto T, Yokota N, Takashima S, Chong Y, Ito Y, Akashi K (2013) Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen. Eur J Haematol 90(2):157-161. doi:10.1111/ejh.12055
11. Corthals SL, Kuiper R, Johnson DC, Sonneveld P, Hajek R, van der Holt B, Magrangeas F, Goldschmidt H, Morgan GJ, Avet-Loiseau H (2011) Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica 96(11):1728-1732. doi:10.3324/haematol.2011. 041434
12. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England journal of medicine 348(26):2609-2617. doi:10.1056/ NEJMoa030288 (Pubitemid 36741588)
13. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127(2):165-172. doi:10.1111/j.1365-2141.2004.05188.x (Pubitemid 39371809)